Compare BridgeBio Pharma Inc (BBIO) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Public Storage — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Public Storage trades at $324.41 (market cap $60.82B). The key difference: Public Storage is far larger — about 3.7× BridgeBio Pharma Inc's market cap, and Public Storage pays a 3.68% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PSA | |
|---|---|---|
Market Cap | $16.61B | $60.82B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $330.47 |
52-Week Low | $47.29 | $258.44 |
Enterprise Value | $18.16B | $75.10B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Public Storage (PSA) trades at $328.40, up 0.43% on the day, with a bullish technical signal from moving averages and a consensus price target of $333.88. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised full-year guidance following the acquisition of National Storage Affiliates. Strong profitability is evident with a net income margin of 41.8% and ROE of 37.42%, though valuation multiples like P/E of 31.34 suggest a premium.
Outlook remains positive due to accretive acquisitions and dividend stability, with a $3.00 quarterly dividend declared. Risks include high valuation, interest rate sensitivity, and integration challenges from recent deals. Analyst sentiment is mixed with 28.6% buy ratings, but institutional activity shows both position increases and cuts, indicating cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
